Long non‐coding RNA ATB expedites non‐small cell lung cancer progression by the miR ‐200b/fibronectin 1 axis
Journal of Clinical Laboratory Analysis · 2023
DOI: 10.1002/jcla.24822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, 2023. Verfasst von Shifang Sun und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics Medicine, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Fibronectins, Lung Neoplasms, MicroRNAs. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 2021 Ningbo Municipal Health Youth Backbone Talent Project, The Natural Science Foundation of Ningbo.
Abstract (Originalsprache)
Background
Long non‐coding RNA (lncRNA) ATB belongs to an active modulator in multiple cancers, but its expression along with potential underlying non‐small cell lung cancer (NSCLC) is obscure. Our study aimed to investigate the role and potential mechanism of LncRNA ATB in NSCLC.
Methods
LncRNA ATB expression in NSCLC tissues and cell lines was detected by qRT‐PCR. Effects of LncRNA ATB on NSCLC cell proliferation, migration and invasion were assessed by MTS, colony formation and transwell assays. The connection among LncRNA ATB, miR‐200b and fibronectin 1 (FN1) was determined by bioformatics prediction and luciferase reporter assay.
Results
In this research, upregulation of LncRNA ATB was discovered in NSCLC tissue samples and cell lines. LncRNA ATB was positively related to advanced tumor phase as well as lymph node metastasis. Cell function assays reflected LncRNA ATB expedited NSCLC cells proliferation, migration and invasion. LncRNA ATB promoted fibronectin 1 (FN1) expression via inhibiting miR‐200b. Furthermore, LncRNA ATB depletion suppressed NSCLC cells proliferation, migration and invasion, while miR‐200b inhibitor or pcDNA‐FN1 rescued these effects.
Conclusion
In summary, our outcomes elucidated that LncRNA ATB/miR‐200b axis expedited NSCLC cells proliferation, migration and invasion by up‐regulating FN1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics Medicine, The Affiliated Hospital of Medical School of Ningbo University, Ningbo, China.
- School of Medicine, Ningbo University, Ningbo, China.
- Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, China.
ORCID-Profile: Shifang Sun
Förderung
- 2021 Ningbo Municipal Health Youth Backbone Talent Project
- The Natural Science Foundation of Ningbo
Zitieren
APA
Sun, S., Zou, Y., Xu, N., Wang, K., Rong, S., Lv, J., Hu, B., Mai, Y., Zhu, D., & Ding, L. (2023). Long non‐coding RNA ATB expedites non‐small cell lung cancer progression by the miR ‐200b/fibronectin 1 axis. Journal of Clinical Laboratory Analysis. https://doi.org/10.1002/jcla.24822
Vancouver
Sun S, Zou Y, Xu N, Wang K, Rong S, Lv J, et al. Long non‐coding RNA ATB expedites non‐small cell lung cancer progression by the miR ‐200b/fibronectin 1 axis. Journal of Clinical Laboratory Analysis. 2023. doi:10.1002/jcla.24822
BibTeX
@article{Sun2023,
author = {Sun, Shifang and Zou, Yifan and Xu, Ningjie and Wang, Kaiyue and Rong, Shanshan and Lv, Jiarong and Hu, Bin and Mai, Yifeng and Zhu, Decai and Ding, Liren},
title = {Long non‐coding RNA ATB expedites non‐small cell lung cancer progression by the miR ‐200b/fibronectin 1 axis},
journal = {Journal of Clinical Laboratory Analysis},
year = {2023},
doi = {10.1002/jcla.24822}
}
EUVIMED